Advances in para-aortic nodal dissection in gastric cancer surgery: A review of research progress over the last decade

Table 3 Main studies that reported clinical data including survival outcomes following chemotherapy and surgery in patients with pathological positivity of para-aortic lymph nodes

Ref.	Registration number	Types of clinical trials (Phase I/II/III)	Published year	Time of accrual	Chemotherapy regimens	Followed by surgery	Extent of lymphadenectomy	Number of patients registered	Incidence of PAN (%)	Primary endpoint	R0 resection rate	Response rate		Survival rate			TRD
												Clinical	Pathological	Relapse-free survival	3-yr (%)	5-yr (%)
Yoshikaw et al[61]	JCOG0001	II	2009	2000-2003	CPT-11/CDDP	Yes	D2 + PAND	55	54.5	3-yr survival rate TRD rate	65 (95%CI 51-78)	56	15	—	27	NA	3/55
Oyama et al[60]	—	—	2012	1990-2008	S-1/CDDP/docetaxel	Yes	D2 + PAND	44	100	—	—	—	87.5	75 (2-yr)	—	—	0/44
Wang et al[64]	—	II	2014	2008-2013	XELOX (capecitabine and oxaliplatin)	Yes	D2	48	100	Response rate of NAC	50%	85.1	49	—	—	—	—
Tsuburayaet al[33]	JCOG0405	II	2014	2005-2007	S-1/CDDP	Yes	D2 + PAND	51	51	R0 resection rate	82(95%CI 69-92)	65	51	—	59	53	0/51
Ito et al[62]	JCOG1002	II	2017	2011-2013	S-1/CDDP/docetaxel	Yes	D2 + PAND	52	43.4	Response rate (RECISTver.1.0)	84.6	57.7	50	—	—	—	0/52
Takahari et al[63]	JCOG1002	II	2019	2011-2013	S-1/CDDP/docetaxel	Yes	D2 + PAND	52	43.4	Clinical RR	—	—	34.6	47.7 (5-yr)	62.7	54.9	0/52

PAN: Para-aortic lymph node; PAND: Para-aortic lymph node dissection; CI: Confidence interval; TRD, treatment-related death .